Sildenafil citrate functions as a Phosphodiesterase-5 Inhibitor. This mechanism of action leads to the potentiation of vasodilation and an increase in uterine blood flow.
Thin Endometrium: VagiLDS is formulated to address cases where the endometrium is thinner than optimal.
Assisted Reproductive Technology (ART): It is intended to support individuals undergoing ART procedures, enhancing the chances of successful conception.
Intrauterine Growth Restriction (IUGR) and Oligohydramniosis VagiLDS is recommended for conditions such as IUGR and Oligohydramniosis, contributing to improved uterine conditions.
Female Sexual Dysfunction: VagiLDS is designed to assist in managing female sexual dysfunction, providing a therapeutic approach to address related concerns.
Mode Of Action:
Sildenafil citrate functions as a Phosphodiesterase-5 Inhibitor, leading to enhanced vasodilation and an increase in uterine blood flow. Following oral administration, Sildenafil Citrate is quickly absorbed, exhibiting an absolute bioavailability of approximately 40%. Its primary route of elimination is through hepatic metabolism, primarily mediated by cytochrome P450 3A4, resulting in the formation of an active metabolite with properties similar to the parent compound, sildenafil. The body rapidly clears sildenafil, with a plasma elimination half-life of around 3–4 hours across the dosage range of 25 to 200 mg.
Salient Features:
- Unique Rapid Release Tablets
- Un-Coated Low Dose Sildenafil Citrate 25mg Tablet
- Designed For Complete Disintegration Within 95 Seconds
Indications:
Dosage:
- As a part of ART Regimen: 3 tablets daily from 5th to 25th day of menstrual cycle.
- In pregnancy complications (IUGR & Oligohydramnios)- 3 tablets daily
- In women planning for a family- 3 tablets daily
Instructions for usage:
As directed by health care provider
STORAGE:
Store in a cool, dry place.
Disclaimer:
In the context of multiple myeloma, leukemia, sickle cell anemia, and specific other medical conditions
Safety
Safe for mother and fetus
FAQ’s:
VagiLDS should be stored according to the instructions on the packaging, typically in a cool, dry place, away from direct sunlight, and out of reach of children.
It is essential to consult with a healthcare provider before taking VagiLDS alongside other medications to ensure compatibility and avoid potential interactions.
VagiLDS is available in a tablet form, and each package contains 10*10 tablets.
The recommended dosage depends on the specific indication:
- As part of an ART regimen: 3 tablets daily from the 5th to the 25th day of the menstrual cycle.
- In pregnancy complications (IUGR & Oligohydramnios): 3 tablets daily.
- In women planning for a family: 3 tablets daily.
VagiLDS is designed for women facing specific health conditions related to thin endometrium, unsuccessful ART, IUGR, oligohydramnios, and female sexual dysfunction. However, individual suitability should be determined in consultation with a healthcare professional.
